HOPE: Using tumor omics to guide precision medicine for head and neck cancer
Official title: Head and Neck Cancer Omics-integrated Precision mEdicine (HOPE)
Run by Samsung Medical Center · NCT07190573 · Data updated 2026-11-12
This project will try using detailed genetic and molecular testing of tumors from adults with head and neck cancer to see if it can help guide more personalized treatment decisions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 350 (estimated) |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | chemotherapy, radiation, pembrolizumab, immunotherapy, cetuximab |
| Locations | 1 site (Seoul, Seoul) |
| Status | Recruiting |
| Started | April 25, 2025 |
| Main results expected | January 31, 2030 |
| Study ends | January 31, 2030 |
| Registry record updated | September 24, 2025 |
| Trial ID | NCT07190573 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 20 years or older with histologically confirmed head and neck cancer who are scheduled to receive or have received appropriate treatment and can provide informed consent are ideal candidates.
✕Probably not a fit
Patients without available tumor tissue, those unable to attend the Seoul center, those who cannot give consent, or whose tumors lack actionable molecular findings may not directly benefit from the program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational program collects tumor and clinical data from adults with histologically confirmed head and neck cancers to generate genomic, transcriptomic, and other molecular profiles. Participants include a broad range of head and neck sites and histologies, including squamous cell carcinoma and salivary gland tumors, whether newly diagnosed or previously treated. Molecular results will be integrated with clinical information to identify potential biomarkers and therapeutic targets, but treatment choices remain determined by treating physicians. The effort aims to build an omics database at Samsung Medical Center to inform future precision oncology approaches in head and neck cancer.
Why it matters
Potential benefit: If successful, this could help match patients to more effective, individualized therapies based on tumor molecular features, potentially improving outcomes and avoiding ineffective treatments.
How similar studies have gone: Similar omics-driven precision oncology approaches have shown promise in other cancers and some head and neck series, but omics-guided personalized treatment for HNC is still an emerging approach with limited definitive survival benefit to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Adults aged 20 years or older
* Histologically confirmed head and neck cancer (including cancers of the oral cavity, pharynx, larynx, nasal cavity, salivary glands, and other head and neck sites) Patients diagnosed at outside institutions but pathologically confirmed as head and neck cancer at Samsung Medical Center are also eligible.)
* Patients with similar histologic types (including squamous cell carcinoma, undifferentiated carcinoma, poorly differentiated carcinoma, nonkeratinizing carcinoma, and adenocarcinoma), as well as cancers of unknown primary, salivary gland cancers, head and neck malignant melanoma, sarcomas, and other malignancies are eligible.
* Diagnosed with head and neckk cancer and scheduled to receive, or previously received, appropriate treatment (radiation therapy, cytotoxic chemotherapy, immune checkpoint inhibitors, or surgery).
* Ability to understand the purpose of the study and willingness to sign informed consent.
Exclusion Criteria:
* Any other condition that, in the opinion of the investigator, makes the patient unsuitable for study participation.
Where it's running
-
Samsung Medical Center
Seoul, Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Nayeon Choi, M.D.
- Email: choinayeon@gmail.com
- Phone: +821089619355
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Airway ultrasound in head and neck cancer patients
This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer
In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
-
Using Silverlon for head and neck patients with tracheostomies
This early-phase study tests whether Silverlon dressings can prevent severe skin reactions under tracheostomy collars in adults with head and neck cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.